- Home
- ODD vs XNCR Comparison
ODD vs XNCR Comparison
Compare ODD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | XNCR |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 845.9M | 881.9M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ODD | XNCR |
|---|---|---|
| Price | $12.51 | $11.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $41.00 | $22.33 |
| AVG Volume (30 Days) | ★ 1.3M | 691.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.92 | $4.80 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $10.80 | $6.92 |
| 52 Week High | $79.18 | $18.69 |
Technical Indicators
Market Signals| Indicator | ODD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 44.32 |
| Support Level | $10.80 | $11.02 |
| Resistance Level | $15.73 | $13.28 |
| Average True Range (ATR) | 1.02 | 0.81 |
| MACD | -0.24 | -0.07 |
| Stochastic Oscillator | 3.76 | 20.00 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.